anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: The increasing implementation of electronic health records allows the use of advanced text-mining methods for establishing new patient phenotypes and stratification, and for revealing outcome correlations. In this study, we aimed to explore the electronic narrative clinical reports of a cohort of patients with Dravet syndrome (DS) longitudinally followed at our center, to identify the capacity of this methodology to retrace natural history of DS during the early years.
METHODS: We used a document-based clinical data warehouse employing natural language processing to recognize the phenotype concepts in the narrative medical reports. We included patients with DS who have a medical report produced before the age of 2 years and a follow-up after the age of 3 years ("DS cohort," 56 individuals). We selected two control populations, a "general control cohort" (275 individuals) and a "neurological control cohort" (281 individuals), with similar characteristics in terms of gender, number of reports, and age at last report. To find concepts specifically associated with DS, we performed a phenome-wide association study using Cox regression, comparing the reports of the three cohorts. We then performed a qualitative analysis of the surviving concepts based on their median age at first appearance.
RESULTS: A total of 76 concepts were prevalent in the reports of children with DS. Concepts appearing during the first 2 years were mostly related with the epilepsy features at the onset of DS (convulsive and prolonged seizures triggered by fever, often requiring in-hospital care). Subsequently, concepts related to new types of seizures and to drug resistance appeared. A series of non-seizure-related concepts emerged after the age of 2-3 years, referring to the nonseizure comorbidities classically associated with DS.
SIGNIFICANCE: The extraction of clinical terms by narrative reports of children with DS allows outlining the known natural history of this rare disease in early childhood. This original model of "longitudinal phenotyping" could be applied to other rare and very rare conditions with poor natural history description.
This ABIGENE pharmacokinetic (PK) study sought mainly to characterize the unchanged drug PK during long-term abiraterone acetate (AA) administration in advanced prostate cancer patients (81 patients). It was observed that individual AA concentrations remained constant over treatment time, with no noticeable changes during repeated long-term drug administration for up to 120 days. There was no correlation between AA concentrations and survival outcomes. However, a significant association between higher AA concentrations and better clinical benefit was observed (p = 0.041). The safety data did not correlate with the AA PK data. A significant positive correlation (r = 0.40, p < 0.001) was observed between mean AA concentration and patient age: the older the patient, the higher the AA concentration. Patient age was found to impact steady-state AA concentration: the older the patient, the higher the mean AA concentration. Altogether, these data may help to guide future research and clinical trials in order to maximize the benefits of AA metastatic castration-resistant prostate cancer patients.
Patients receive talazoparib PO QD on days 1-28 and axitinib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patient may continue treatment even if there is progression of disease as long as the patient remains clinically stable, per the treating physician's discretion.
The key to saving lives is to achieve instant and effective sealing hemostasis in the event of emergency bleeding. Herein, a plant oil-based EMTA/Zn2+ bioadhesive is prepared by a facile reaction of epoxidized soybean oil (ESO) with methacrylic acid (MAA) and tannic acid (TA), followed by the addition of zinc ions for coordination with TA. The EMTA/Zn2+ bioadhesive can be rapidly cured in situ at the wound site through photo-cross-linking under ultraviolet (UV) light-emitting diode (LED) irradiation within 30 s, achieving ultrastrong wet-tissue adhesion performance of 92.4 and 51.8 kPa to porcine skin and aortic skin after 7 days underwater, respectively. Especially, the EMTA/Zn2+ bioadhesive exhibits outstanding sealing performance in vitro with the high burst pressure of 525 mmHg (70 kPa) and 337.5 mmHg (45 kPa) to porcine skin and aortic skin, respectively. Moreover, the EMTA/Zn2+ bioadhesive not only has outstanding hemocompatibility and good biodegradability but also exhibits excellent cytocompatibility and antibacterial properties. Notably, the EMTA/Zn2+ bioadhesive has remarkable instant sealing hemostatic ability for hemorrhaging liver in vivo. Therefore, the prepared plant oil-based EMTA/Zn2+ bioadhesive can serve as a charming alternative candidate for instant sealing hemostasis in clinical applications, especially in traumatic internal organs and arterial bleeding.
Disclosed is a gout soup tea preparation method. Gout soup tea is prepared from root of gossampinus malabarica (DC.) Merr and an old hen in a combined manner. The gout soup tea preparation method has the advantages that required raw materials are rich in resources, low in price and easy to implement. The pure natural root of the gossampinus malabarica (DC.) Merr and the old hen one year old or more are selected as the raw materials, and accordingly the prepared gout soup tea is low in cost, harmless to a human body, good in gout efficacy, excellent in taste, good in tonic effect, wide in health care range, unlimited in drinking population and the like. After drinking the gout soup tea, gout patients don't need to take an injection or abstain from certain food, and the gout soup tea is high in cure rate, thereby being worthy of being popularized energetically.
Participants with mild renal impairment (eGFR 60 to less than \[\<\] 90 mL/min) will be enrolled. Participants will receive a single SC dose of JNJ-64565111 on Day 1.
The purpose of this protocol is to extend our existing patient base from those with prostate cancer to those with any solid malignancy - as well as patients with schwannoma, a non-malignant solid tumor that also over-expresses GCP II. Using our first generation imaging agent, \[18F\]DCFBC, we have shown that we could detect GCP II in tissue specimens of patients with a variety of cancers, and vestibular schwannoma. We have also shown that GCP II may not only be present in the neovasculature of solid (non-prostate) tumors, but also reside within the tumor epithelium itself. We have shown that to be the case for melanoma, in particular. Our goal is to leverage the broad utility of our GCP II targeted imaging agents for managing other cancers. In addition to schwannoma, the cancers we intend to target include but will not be restricted to: head and neck cancer, salivary gland tumors, renal cell carcinoma, transitional cell carcinoma, colorectal cancer, gastric cancer, neuroendocrine cancer, glioblastoma, melanoma, pancreatic cancer, non-small cell lung cancer, soft tissue sarcoma, breast cancer, endometrial cancer, ovarian cancer, lymphoma and multiple myeloma.
Biocompatible fluorocarbon emulsions having fluorocarbon in concentrations of from 75% weight per volume to 125% weight per volume have small, biocompatible particle size stability through heat sterilization with one emulsifying agent, including phospholipids, in concentrations of from 3% to 7% weight per volume. The single emulsifying agent can be hydrogenated lecithins and synthesized lecithins. Fluorocarbon emulsions having fluorocarbon in concentrations of from 40% weight per volume to 125% weight per volume have stability of partial pressure of oxygen and of partial pressure of carbon dioxide through heat sterilization and storage for extended periods of time after having been oxygenated with dissolved oxygen. A method of preparing biocompatible fluorocarbon emulsions includes preparing a mixture of an emulsifying agent, osmotic agent, buffering agent, aqueous phase and fluorocarbon, forcing the mixture under high pressure into a cavity, against a surface and around a lip to cause turbulence and possibly cavitation to form high fluorocarbon concentration emulsions that are stable through heat sterilization; and, even when oxygenated, maintain substantially stable partial pressures of oxygen and of carbon dioxide, and substantially stable pH. A method of oxygenating high fluorocarbon concentration emuslions includes placing a measured amount of the emulsion in a container and causing the emulsion to form a thin film around the inner surface of the container when the oxygen is injected. An alternative method of oxygenating the high fluorocarbon concentration emulsion includes a two container system where one container, permeable to the to be dissolved gas, is formed within the other, and the emulsion is injected in one container and the to be dissolved gas is injected into the other container.
A 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and leucovorin (400 mg/m2), administered simultaneously over a 2-hour infusion period. Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating every 14 days for 12 cycles.
PURPOSE: To obtain the subject oral composition for an analgesic or antiinflammatory agent, etc., capable of quickly exhibiting pharmaceutical effect by compounding a specific amount of a salt of a basic amino acid such as L-arginine or L-lysine and S(+)-ibuprofen with a vehicle. CONSTITUTION: A basic amino acid such as L-arginine or L-lysine is made to react with S(+)-ibuprofen to form S(+)-ibuprofen alginate, S(+)-ibuprofen lysinate, etc. The obtained salt is sieved and put in a mixer. Saccharose and flavor are added and mixed. The salt of >=200 mg expressed in terms of the amount of S(+)-ibuprofen is formulated using a pharmaceutically permissible vehicle to obtain the objective pharmaceutical composition. The composition can quickly exhibit pharmaceutical effect and is useful for treating chronic rheumatoid arthritis, myelitis with rigidity, para-arthritis, extraarticular rheumatic disease, etc., as analgesic and antiinflammatory agent.
The invention relates to compositions and methods for taste-masking bitter, unpleasant tasting medicaments. The invention further relates to taste-masked coated granules of a bitter pharmaceutical agent that can be reconstituted as a liquid suspension. The taste-masked pharmaceutical granule composition includes a core, a first coating layer and a second coating layer. The core includes one or more bitter tasting pharmaceutically active agents, one or more hydrocolloid materials, and, optionally, one or more flavoring agents. The first coating layer includes one or more hydrophobic materials and covers at least a portion of the core. The second coating layer includes one or more enteric film forming polymers and one or more waxy materials and covers at least a part of the first coating layer.
BACKGROUND: Rabbits are popular family pets. They are prey species and so have evolved to hide signs of illness and pain. Recent research has developed robust pain scales for use in a clinical setting, but to date none has examined rabbit owners' ability to recognise pain in their animals. This study investigated how owners identify pain in their pet rabbits and their ability to correctly identify different levels of pain, in order to determine any need for owner education in this area.
METHODS: Owners were recruited via Facebook and a two-part online survey was distributed. Part one collected data on demographics, owners' knowledge of pain signs and beliefs about pain in rabbits. Part two asked respondents to pain score eight videos of rabbits in different levels of pain for comparison to pain scores made by three experts. We used a simplified version of the Bristol Rabbit Pain Score (BRPS) which involved a single 0 to 3 scale. We explored the number of pain signs each respondent could list, the total score given to the videos, and their deviation from the experts' scores.
RESULTS: A total of 500 respondents completed part one of the survey and 345 additionally completed Part two. Respondents were on average able to state five signs of pain (range 0-12), but females stated significantly more (p = 0.018), as did those who worked with rabbits (p = 0.004) and those with experience of their rabbit having an operation (p = 0.01). Overall, 98.6% of respondents thought rabbits felt pain as much or more that dogs and cats. In Part two, respondents more frequently agreed with the experts when identifying rabbits in no pain (88.8%) and severe pain (65.2%), but there was lower agreement when identifying mild (28.4%) and moderate pain (43.2%). Respondents overall rated pain lower than experts with an average total pain score of 11.9 compared to 18 given by the experts.
CONCLUSIONS: Most rabbit owners are able to list numerous pain signs and are generally able to identify pain-free rabbits and those in severe pain. Owners' ability to differentiate between mild and moderate pain is more limited and could benefit from training in the subtler signs of pain. Veterinary professionals are well placed to educate owners about signs of pain in rabbits and should be aware of areas where owners' knowledge can be improved.
Disclosed is a method for controlling user access to a medical system, the medical system including a medical device (1) and remote controller (2). The method includes providing the medical device (1) comprising a medical device communication unit (13). The method includes providing the remote controller (2) as separate device from the medical device (1), the remote controller (2) comprising a remote controller user interface (24a, 24b) and a remote controller communication unit (23). The remote controller (2) is designed for entering, via the remote controller user interface (24a, 25b), at least one medical device command for execution by the medical device (1), wherein the medical device communication unit (13) and the remote controller communication unit (23) are adapted for data exchange. The method further includes controlling the remote controller (2) to be in a locked state, wherein, in the locked state, entering of the at least one medical device command and execution of the further command is disabled. The method further includes, in the locked state, requesting the entry of an identification code via the remote controller user interface (24a, 24b) and switching, upon correct entry of the identification code, the remote controller (2) into an unlocked state, wherein, in the unlocked state, entering of the at least one medical device command is enabled. The method further includes alternatively determining by the medical system, whether a safety condition is met, and executing, if the safety condition is met, a further command.
FIELD: medicine, oncology. SUBSTANCE: invention relates to methods of treatment of patients with incurable cancer forms. Method involves administration of viturid in the dose 10 ml, 3 times per 24 h, adebit in the dose by 2 tablets, 2 times per a day, L-thyroxine-100 in the dose 1 tablet in the morning, vitamin C in the dose 2.0 ml of 50% solution by intramuscular route, 20 injections per course, in combination with diet N 9. For detoxication tubages are carried out with 100 ml of 33% magnesium sulfate solution, 3 times per a month, hemodez is administrated in the dose 400 ml, 3 times per a month, or hemosorption is carried out. Method provides correction of metabolic processes in oncological patients. EFFECT: enhanced effectiveness of treatment of cancer patients.
Body Mass Index (BMI) according to WHO definition. BMI \< 25 is defined as 'normal weight'.
PURPOSE:To produce a new compound having an acyl coenzyme A cholesterol transferase inhibitory effect and useful for prevention and therapy of diseases, e.g. human hyperlipidemia caused by accumulation of cholesterol and adult diseases such as arteriosclerosis. CONSTITUTION:A compound is expressed by formula I (R is H or COCH3; Y is OH, OCOCH3 or O; X is O or NCH2CH2OH; the dotted line represents a single bond or a double bond), e.g. the compound of formula II. The compound of formula I can be produced by culturing a microorganism belonging to Penicillium preferably Penicillium sp. FO-3216 (FERM-P-14152) preferably at pH5 and 27 deg.C for 1 to 2 days.
Brain imaging studies have reported that the neural deficits of congenital amusia in non-tonal language speakers are mainly in the connectivity between the auditory cortex and the inferior frontal gyrus (IFG) in the right hemisphere. However, the relationship between the functional connectivity (FC) in these regions and the music perception ability of amusia in tonal language speakers remains unclear. In this study, we investigated the FC characteristics of amusia in Mandarin speakers in resting-state functional magnetic resonance imaging data by voxel-wise connectivity analyses with seeds in left and right Heschl's gyri (HG) and region of interest (ROI)-to-ROI connectivity analyses. Our findings indicate increased connectivity between right HG and bilateral posterior superior temporal gyrus, as determined by voxel-wise connectivity analyses in amusia. Conversely, reduced connectivity was observed between bilateral HG and bilateral IFG (orbital part) as assessed through ROI-to-ROI connectivity analyses in amusia when compared to controls. Moreover, the music perception scores of amusia in Mandarin speakers were associated with diminished connectivity between the left HG and the right IFG. This study furnishes direct evidence for the link between music perception deficits and the aberrant frontotemporal connectivity of congenital amusia in tonal language speakers in resting state.
All asymptomatic pregnant women who are undergoing routine obstetric ultrasound evaluations at any gestational age who elect to undergo cardiovascular sonographic assessment for research purposes at no cost. All participants must be over the age of 18 and capable of consenting to the study (conscious, with capacity for medical decision making for themselves).
The invention relates to the field of medicines, in particular to a polypeptide compound for treating or preventing atherosclerosis. Leptin excitation polypeptide is characterized in that the sequence of the leptin excitation polypeptide is TLSKMDQTLAVYQQILTSMP. The leptin excitation polypeptide is prepared by adopting an Fmoc protective solid phase synthesis technology. The leptin excitation polypeptide can be covalently connected to an adjuvant; the adjuvant is bovine serum albumin, human serum albumin or polyethylene glycol. The invention also discloses the application of the leptin excitation polypeptide in treating diseases related to the atherosclerosis. The diseases related to the atherosclerosis comprises angina, myocardial infarction, arrhythmia, cerebral apoplexy, encephalatrophy, resistant hypertension, renal insufficiency and the like. The leptin excitation polypeptide provided by the invention can promote a leptin precursor to be decomposed into active leptin in a targeted manner, promote the secretion of leptin, and achieve the effects of preventing or treating the atherosclerosis.
In order to provide decision-making support for the auxiliary diagnosis and individualized treatment of calculous pyonephrosis, the study aims to analyze the clinical features of the condition, investigate its risk factors, and develop a prediction model of the condition using machine learning techniques. A retrospective analysis was conducted on the clinical data of 268 patients with calculous renal pelvic effusion who underwent ultrasonography-guided percutaneous renal puncture and drainage in our hospital during January 2018 to December 2022. The patients were included into two groups, one for pyonephrosis and the other for hydronephrosis. At a random ratio of 7:3, the research cohort was split into training and testing data sets. Single factor analysis was utilized to examine the 43 characteristics of the hydronephrosis group and the pyonephrosis group using the T test, Spearman rank correlation test and chi-square test. Disparities in the characteristic distributions between the two groups in the training and test sets were noted. The features were filtered using the minimal absolute value shrinkage and selection operator on the training set of data. Auxiliary diagnostic prediction models were established using the following five machine learning (ML) algorithms: random forest (RF), xtreme gradient boosting (XGBoost), support vector machines (SVM), gradient boosting decision trees (GBDT) and logistic regression (LR). The area under the curve (AUC) was used to compare the performance, and the best model was chosen. The decision curve was used to evaluate the clinical practicability of the models. The models with the greatest AUC in the training dataset were RF (1.000), followed by XGBoost (0.999), GBDT (0.977), and SVM (0.971). The lowest AUC was obtained by LR (0.938). With the greatest AUC in the test dataset going to GBDT (0.967), followed by LR (0.957), XGBoost (0.950), SVM (0.939) and RF (0.924). LR, GBDT and RF models had the highest accuracy were 0.873, followed by SVM, and the lowest was XGBoost. Out of the five models, the LR model had the best sensitivity and specificity is 0.923 and 0.887. The GBDT model had the highest AUC among the five models of calculous pyonephrosis developed using the ML, followed by the LR model. The LR model was considered be the best prediction model when combined with clinical operability. As it comes to diagnosing pyonephrosis, the LR model was more credible and had better prediction accuracy than common analysis approaches. Its nomogram can be used as an additional non-invasive diagnostic technique.
Intervention patients will engage in a 16-week program where they will receive regular health promotion messaging about (a) food, nutrition, and diet; and (b) exercise and physical activity. Intervention patients will be asked to track patient generated health data (PGHD) elements related to weight management through a mobile health app loaded on their phones and/or through using a fitness tracker, depending on patient preference, and to share that information with the research team. Patient-reported outcomes (PRO) measures will be collected pre-and-post-intervention. Intervention patients will also be asked to provide answers to patient-reported outcomes measures on a weekly basis.
PROBLEM TO BE SOLVED: To obtain a hydroxy apatite by heat treating calcium phosphate in a specific temp. range in the presence of water. SOLUTION: The high crystalline hydroxy apatite is obtained by heat treating calcium phosphate at 700-200 deg.C in the presence of water. As the calcium phosphate, sludge containing calcium phosphate obtained by adding an alkaline calcium such as calcium hydroxide into waste water or waste oil generated in the production process of an inorganic or organic phosphorus compound and containing phosphorus matter is preferable and calcium phosphate or calcium polyphosphate obtained by the reaction of phosphoric acid with an alkaline calcium compound such as calcium hydroxide is desirable. The raw material calcium phosphate is mixed with 0.2-5 times by weight of water to form water slurry or wet cake and heat treated it at 800-1200 deg.C in an electric furnace, or the like. Because the sludge containing calcium phosphate is used, the phosphorus source is effectively utilized.